Multicenter phase II study of lurbinectedin in BRCAMutated and unselected metastatic advanced breast cancer and biomarker assessment substudy Academic Article uri icon

Overview

MeSH Major

  • Cathepsin B
  • Drug Carriers
  • Maytansine
  • Nanofibers
  • Oligopeptides
  • Tubulin Modulators

abstract

  • Lurbinectedin showed noteworthy activity in patients with BRCA1/2 mutations. Response and survival was notable in those with BRCA2 mutations. Additional clinical development in this subset of patients with metastatic breast cancer is warranted.

publication date

  • November 2018

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC6209089

Digital Object Identifier (DOI)

  • 10.1200/JCO.2018.78.6558

PubMed ID

  • 30240327

Additional Document Info

start page

  • JCO2018786558

volume

  • 36

number

  • 31